Comment je traite.... Un carcinome basocellulaire par l'imiquimod topique (Aldara).

Pierard-Franchimont, Claudine; Nikkels, Arjen; Paquet, Philippe; Quatresooz, Pascale; Pierard, Gérald

Download

Article (Scientific journals)

Comment je traite.... Un carcinome basocellulaire par l'imiquimod topique (Aldara).

Pierard-Franchimont, Claudine; Nikkels, Arjen; Paquet, Philippe et al.

2005 • In Revue Médicale de Liège, 60 (4), p. 207-209

Peer reviewed

Permalink
https://hdl.handle.net/2268/9388

PubMed
15943094

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

COMMENT...IMIQUIMOD.pdf

Publisher postprint (516.93 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adjuvants, Immunologic/therapeutic use; Aminoquinolines/therapeutic use; Carcinoma, Basal Cell/drug therapy; Humans; Skin Neoplasms/drug therapy

Abstract :

[en] Basal cell carcinoma is the most frequent cancer in humans. Several clinical types are distinguished. They are bound to distinct evolutive prognosis. The surgical excision is the treatment of choice which is rarely followed by recurrence. However, when the lesion is superficial and non aggressive and when the body site is adequate, topical applications of imiquimod can provoke the neoplastic regression. This type of immunotherapy brings 70 to 90% complete remission. A medical follow-up of the treated site is mandatory for a couple of years.

Disciplines :

Dermatology

Author, co-author :

Pierard-Franchimont, Claudine ; Université de Liège - ULiège > Dermatopathologie

Nikkels, Arjen ; Université de Liège - ULiège > Dermatologie

Paquet, Philippe ; Université de Liège - ULiège > Dermatopathologie

Quatresooz, Pascale ; Université de Liège - ULiège > Dermatopathologie

Pierard, Gérald ; Université de Liège - ULiège > Dermatopathologie

Language :

French

Title :

Comment je traite.... Un carcinome basocellulaire par l'imiquimod topique (Aldara).

Alternative titles :

[en] How I treat ... basal cell carcinoma by imiquimod.

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

207-209

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 March 2009

Statistics

Number of views

248 (6 by ULiège)

Number of downloads

495 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Piérard-Franchimont C. et Piérard GE.- Tumeurs cutanées fréquentes en gériatrie. Rev Med Liège, 1997, 52, 289-295.
Stern RS.- The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol, 1999, 135, 843-844.
Uhoda I, Quatresooz P, Fumal I, et al.- Updating trends in cutaneous cancers in south-east Belgium. Oncol Reports, 2004, 12, 111-114.
Holikova Z, Massi D, Lotti T, Hercogova J.- Insight into the pathogenesis of sporadic basal cell carcinoma. Int J Dermatol, 2004, 43, 865-869.
MacKie RM.- Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe. J Eur Acad Dermatol Venereol, 2004, 18, 552-555.
Kuijpers DIM, Thissen RTM, Neumann HA.- Basal cell carcinoma. Treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol, 2002, 3, 247-259.
Beutner KR, Geisse JK, Helman D, et al.- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol, 1999, 41, 1002-1007.
Hannuksela-Svahn A, Nordal E, Christiensen OB.- Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream. Acta Derm Venereol, 2000, 80, 381-382.
Kagy MK, Amonette R.- The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg, 2000, 26, 577-578.
Marks R, Gebauer K, Shumack S, et al.- Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol, 2001, 44, 807-813.
Hermanns-Lê T, Nikkels AF, Uhoda I, et al.- L'imiquimod (Aldara®): un immunomodulateur pour la peau. Rev Med Liège, 2002, 57, 116-118.
Micali G, De Pasquale R, Caltabiano R, et al.- Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatol Treat, 2002, 13, 123-127.
Shumack S, Robinson J, Kossard S, et al.- Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol, 2002, 138, 1165-1171.
Sterry W, Herera E, Takwale A, et al.- Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol, 2002, 147, 1227-1236.
Stockfleth E, Ulrich C, Hauschild A, et al.- Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol, 2002, 12, 569-572.
Weisberg NK, Varghese M.- Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg, 2002, 28, 518-523.
Eklind J, Tartler U, Machke J, et al.- Imiquimod to treat different cancers of the epidermis. Dermatol Surg, 2003, 29, 890-896.
Gaspar AA, Spuder DN.- Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg, 2003, 29, 1027-1034.
Geisse J, Caro I, Lindholm J et al.- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol, 2004, 50, 722-733.
Urosevic M, Dummer R.- Role of imiquimod in skin cancer treatment. Am J Clin Dermatol, 2004, 5, 453-458.
Stanley MA.- Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol, 2002, 27, 571-577.
Urosevic M, Maier T, Benninghoff B et al.- Mechanisms underlying Imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol, 2003, 139, 1325-1332.
Suzuki H, Wang B, Shiviji GM, et al.- Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000, 114, 135-141.
Arrese JE, Paquet P, Claessens N, et al.- Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001, 28, 131-134.
Hermanns-Lê T, Paquet P, Nikkels AF, et al.- Prolonged imiquimod treatment and graft-versus-host reaction: histological mimicry in the pattern of monocyte macrophage-dendrocyte lineage skin infiltration. Dermatology, 2003, 206, 361-365.
Quatresooz P, Piérard GE.- Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol, 2003, 28, S27-S29.
Uhoda I, Quatresooz P, Piérard-Franchimont C, Piérard GE.- Nudging epidermal field cancerogenesis by imiquimod. Dermatology, 2003, 206, 357-360.
Schön M, Bong AB, Drewniok C et al.- Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst, 2003, 95, 1138-1149.
Sullivan TP, Dearaujo T, Vincek V et al.- Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream of vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg, 2003, 29, 1181-1185.
Schön MP, Schön M.- Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis, 2004, 9, 291-298.
Bourguignon R, Paquet P, Quatresooz P, Piérard GE.-Comment je traite... un lentigo malin par rimiquimod topique (Aldara®). Rev Med Liège, sous presse.
Zitelli JA.- Use of imiquimod for treating skin cancer. J Am Acad Dermatol, 2005, 52, 177.